

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type (NHS Permission / HRA Approval)	Project Short title	Date of First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Date Site Ready to Start	Non Confirmation Status	Reason for delay in recruiting first participant
1	16/EE/0294	199550	HRA Approvals	AIM HY-INFORM	13/03/2017	No	23/06/2016	01/11/2016	21/12/2016	01/11/2016	10/02/2017	02/03/2017	02/03/2017		Contracting delays
2	16/YH/0438	208755	HRA Approvals	Prebiotics in Immunity and Inflammation V1	22/02/2017	No	23/09/2016	06/10/2016	11/11/2016	08/11/2016	11/11/2016	11/11/2016	11/11/2016		No eligible patients seen during the reported period
3	16/LO/1118	148223	HRA Approvals	PAGE		No	10/05/2016	02/03/2016	23/01/2017	15/12/2016	27/02/2017	27/02/2017	27/02/2017		No eligible patients seen during the reported period
4	16/SC/0147	183044	HRA Approvals	TriMaster v1		No		08/08/2016	13/02/2017	07/07/2016	14/02/2017	14/02/2017	14/02/2017		No eligible patients seen during the reported period
5	16/LO/2107	194377	HRA Approvals	MRI-augmented Guidance for Congenital Cardiovascular Interventions		No		27/01/2016	08/03/2017	08/03/2017	10/03/2017	10/03/2017	10/03/2017		No eligible patients seen during the reported period
6	17/LO/0621	191390	HRA Approvals	STARRT-AKI	27/07/2017	No	24/03/2017	23/01/2017	11/04/2017	22/05/2017	23/05/2017	23/05/2017	23/05/2017		Relevant permissions delayed and not granted in time
7	17/SC/0225	213138	HRA Approvals	MagnUM Pilot Study		No		08/02/2017	12/04/2017	03/07/2017	10/07/2017	10/07/2017	10/07/2017		Relevant permissions delayed and not granted in time
8	17/LO/0766	174084	HRA Approvals	Mindfulness Meditation to treat Insomnia		No		11/11/2016	26/04/2017	26/06/2017	28/07/2017	28/07/2017	28/07/2017		Relevant permissions delayed and not granted in time
9	17/YH/0074	219173	HRA Approvals	SPIRIT trial - Version 1.0	28/09/2017	No	23/02/2017	27/02/2017	05/05/2017	13/04/2017	14/06/2017	14/06/2017	14/06/2017		No eligible patients seen during the reported period
10	17/LO/0417	201101	HRA Approvals	GAP 4 INTERVAL - MCRPC v3.0		No		27/06/2016	19/05/2017	15/06/2017	31/08/2017	31/08/2017	31/08/2017		Relevant permissions delayed and not granted in time
11	16/WS/0057	193580	HRA Approvals	The MENAC Trial		No		18/08/2016	21/10/2016	04/08/2016	27/03/2017	27/03/2017	27/03/2017		Contracting delays
12	16/LO/1636	172808	HRA Approvals	POEM vs Dilatation		No		23/11/2016	23/11/2016	03/11/2016	15/02/2017	15/02/2017	15/02/2017		Relevant permissions delayed and not granted in time
13	15/wa/0391	180498	HRA Approvals	MONOCLE	03/07/2017	No		28/11/2016	04/01/2017	16/11/2016	06/06/2017	19/06/2017	23/06/2017		Contracting delays
14	16/WS/0197	186191	HRA Approvals	ATLANTIS		No	20/04/2017	03/02/2017	03/02/2017	01/02/2017					Relevant permissions delayed and not granted in time
15	17/LO/0120	159481	HRA Approvals	PAS Pilot Trial	02/08/2017	No		15/03/2017	21/03/2017	14/03/2017	07/06/2017	27/06/2017	28/06/2017		Contracting delays
16	17/LO/0568	215024	HRA Approvals	Motivating Structured walking Activity in Intermittent Claudication		No		09/12/2016	27/04/2017	27/04/2017	06/06/2017	06/06/2017	06/06/2017		Staff availability issues at site
17	17/LO/0038	182633	HRA Approvals	UK P3BP Trial		No		22/05/2017	22/05/2017	06/04/2017					Relevant permissions delayed and not granted in time
18	17/LO/0789	222391	HRA Approvals	EVOTION v1.0		No		26/05/2017	26/05/2017	31/05/2017	17/07/2017	17/07/2017	17/07/2017		Relevant permissions delayed and not granted in time
19	16/LO/1177	208134	HRA Approvals	ECMO ULTRASOUND (ECMO USS)	11/01/2017	No	08/06/2016	19/05/2016	16/10/2016	16/10/2016	17/11/2016	17/11/2016	17/11/2016		Delays caused by sponsor
20	16/EM/0344	180454	HRA Approvals	MPP VARR	14/03/2017	No	26/07/2016	09/02/2016	26/10/2016	26/10/2016	26/10/2016	26/10/2016	26/10/2016		Delays caused by sponsor
21	16/LO/1069	200813	HRA Approvals	PALLAS: PALbociclib CoLaborative Adjuvant Study		No	11/01/2016	29/03/2016	28/10/2016	06/09/2016	30/05/2017	30/05/2017	30/05/2017		Contracting delays
22	16/LO/1947	209757	HRA Approvals	Lixisenatide Arterial Stiffness Trial (LAST) Version 3.0	09/05/2017	No	17/11/2016	18/05/2016	12/12/2016	12/12/2016	18/01/2017	18/01/2017	18/01/2017		Delays caused by sponsor
23	16/NE/0279	198051	HRA Approvals	TIDaL		No		29/09/2016	13/01/2017	29/09/2016	04/05/2017	19/05/2017	18/08/2017		Contracting delays
24	16/LO/1024	195085	HRA Approvals	BEAT LUPUS		No	06/09/2016	18/03/2016	15/01/2017	20/09/2016	03/02/2017	22/02/2017	22/02/2017		Delays caused by sponsor and No eligible patients seen during the reported period
25	16/LO/0831	196728	HRA Approvals	CAP-IT	09/05/2017	No		25/07/2016	02/02/2017	11/11/2016	05/04/2017	13/04/2017	13/04/2017		Delays caused by sponsor
26	17/LO/0094	202316	HRA Approvals	R-PREP	19/09/2017	No	21/12/2016	15/06/2016	17/02/2017	05/06/2017	28/07/2017	28/07/2017	28/07/2017		Delays caused by sponsor and Relevant permissions delayed not granted in time
27	17/LO/0158	214134	HRA Approvals	Preparing patients and families for cancer chemotherapy		No	09/01/2017	27/09/2016	13/04/2017	13/04/2017	08/08/2017	08/08/2017	08/08/2017		Delays caused by sponsor
28	16/LO/1992	216381	HRA Approvals	Hypoglycaemia Awareness Restoration Programme - the RCT v1.0	05/07/2017	No	20/10/2016	19/01/2017	18/04/2017	10/01/2017	22/05/2017	07/06/2017	03/07/2017		Contracting delays
29	17/LO/0442	212312	HRA Approvals	High risk lung health clinic	18/07/2017	No	22/02/2017	22/12/2016	28/04/2017	28/04/2017	29/06/2017	29/06/2017	29/06/2017		Contracting delays
30	17/LO/0427	199962	HRA Approvals	N3		No		12/04/2017	03/05/2017	30/06/2017					Delays caused by sponsor
31	16/NW/0517	188554	HRA Approvals	Myeloma XII (ACCoRd trial) Version 1.0		Within 70 Days	29/03/2017	13/06/2017	02/08/2017	27/10/2016					Relevant permissions delayed and not granted in time and Contracting delays
32	16/LO/1422	179204	HRA Approvals	SWAN A 2 arm feasibility trial to support postnatal weight management	18/11/2016	Yes	21/07/2016	08/03/2016	11/10/2016	11/10/2016	18/10/2016	18/10/2016	18/10/2016		Met 70 Day benchmark
33	16/LO/1205	193598	HRA Approvals	Psychoeducational intervention for women prescribed tamoxifen	26/10/2016	Yes	10/06/2016	09/03/2016	13/10/2016	13/10/2016	20/10/2016	20/10/2016	20/10/2016		Met 70 Day benchmark
34	16/SC/0478	192947	HRA Approvals	CXCR2 inhibition and coronary heart disease / CICADA	29/11/2016	Yes	22/08/2016	12/05/2016	17/10/2016	01/11/2016	08/11/2016	08/11/2016	08/11/2016		Met 70 Day benchmark
35	16/SC/0438	204711	HRA Approvals	Pre-EMPT Version 1	29/11/2016	Yes	27/07/2016	05/04/2016	28/10/2016	28/10/2016	17/11/2016	17/11/2016	17/11/2016		Met 70 Day benchmark
36	16/LO/1130	187152	HRA Approvals	Cereal bar or oral supplementation with tablets (BOOST)	05/12/2016	Yes	18/05/2016	16/02/2016	01/11/2016	01/11/2016	09/11/2016	09/11/2016	09/11/2016		Met 70 Day benchmark
37	16/SC/0345	206835	HRA Approvals	Safety, immunogenicity and efficacy of RHS.1/AS01 (VAC063)	10/01/2017	Yes		29/06/2016	22/11/2016	31/08/2016	24/11/2016	15/12/2016	15/12/2016		Met 70 Day benchmark
38	16/SW/0348	215681	HRA Approvals	MR-simulation in Radiotherapy for Prostate Cancer	09/03/2017	Yes	16/12/2016	13/09/2016	11/01/2017	24/02/2017	01/03/2017	01/03/2017	01/03/2017		Met 70 Day benchmark
39	17/LO/0050	212827	HRA Approvals	Feasibility study to support medication adherence following ACS	08/03/2017	Yes	16/12/2016	22/11/2016	24/01/2017	22/02/2017	23/02/2017	23/02/2017	23/02/2017		Met 70 Day benchmark
40	17/LO/0420	213515	HRA Approvals	Proof of Concept study for a dressing glove	11/05/2017	Yes	20/02/2017	21/12/2016	10/03/2017	07/04/2017	18/04/2017	18/04/2017	18/04/2017		Met 70 Day benchmark
41	17/NW/0268	215589	HRA Approvals	ENHANCE	03/07/2017	Yes	12/04/2017	14/10/2016	25/04/2017	24/05/2017	30/05/2017	30/05/2017	30/05/2017		Met 70 Day benchmark
42	16/LO/1769	209909	HRA Approvals	ASTAR	16/08/2017	Yes		25/04/2017	28/06/2017	04/01/2017	13/07/2017	12/07/2017	12/07/2017		Met 70 Day benchmark
43	16/LO/1210	204009	HRA Approvals	ILTSD		No		08/03/2016	10/11/2016	10/11/2016	08/09/2017	08/09/2017	08/09/2017		Relevant permissions delayed and not granted in time
44	16/NW/0791	212340	HRA Approvals	MODIFY	19/04/2017	No		12/09/2016	02/02/2017	02/02/2017	05/04/2017	05/04/2017	05/04/2017		Relevant permissions delayed and not granted in time

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type (NHS Permission / HRA Approval)	Project Short title	Date of First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Date Site Ready to Start	Non Confirmation Status	Reason for delay in recruiting first participant
45	17/WM/0017	201600	HRA Approvals	MifeMiso		No		20/02/2017	04/07/2017	18/04/2017	21/06/2017	07/07/2017	21/08/2017		No eligible patients seen during the reported period
46	16/SS/0014	187949	HRA Approvals	GEM3	20/06/2017	No		16/11/2016	10/02/2017	14/10/2016	01/03/2017	15/03/2017	02/05/2017		Delays caused by sponsor
47	17/SC/0231	221097	HRA Approvals	Pembrolizumab versus standard therapy in mesothelioma (PROMISE-meso)		No		23/03/2017	20/06/2017	27/06/2017	09/10/2017	09/10/2017	09/10/2017		Delays caused by sponsor
48	16/NW/0557	198661	HRA Approvals	CHronic HypERTension and L-citRulline study (CHERRY)		No		28/02/2017	30/06/2017	23/03/2017					Delays caused by sponsor
49	17/LO/0659	223015	HRA Approvals	EPICC-ID Randomised Controlled Trial		No		19/05/2017	07/07/2017	19/05/2017	04/09/2017	04/09/2017	04/09/2017		Delays caused by sponsor
50	17/NE/0195	193713	HRA Approvals	MOLL trial		Within 70 Days		01/03/2017	02/08/2017	02/08/2017	14/08/2017	14/08/2017	14/08/2017		Within 70 days
51	17/NE/0271	227647	HRA Approvals	HMB-ICU Reproducibility		Within 70 Days		23/05/2017	14/09/2017	14/09/2017					Within 70 days
52	17/EM/0375	223704	HRA Approvals	Prostpective RandOmsed Trial of Emergency Cardiac CT: (PROTECT CT)		Within 70 Days		04/04/2017	20/09/2017						Within 70 days
53	17/WM/0241	224978	HRA Approvals	BUMP		Within 70 Days		22/08/2017	27/09/2017	09/08/2017					Within 70 days
54	16/LO/1910	212398	HRA Approvals	Impact of almond nut consumption on markers of CVD & metabolic disease	24/04/2017	Yes	05/10/2016	01/08/2016	13/03/2017	13/03/2017	13/03/2017	13/03/2017	13/03/2017		Met 70 Day benchmark
55	17/EE/0169	213576	HRA Approvals	An RCT comparing bond failure of two types of molar buccal tubes	12/05/2017	Yes		31/10/2016	27/04/2017	27/04/2017	05/05/2017	05/05/2017	05/05/2017		Met 70 Day benchmark
56	17/ES/0067	223614	HRA Approvals	Feasibility of Minimal Invasive Dentistry (MID) in dental phobia	27/07/2017	Yes	16/05/2017	31/01/2017	03/07/2017	03/07/2017	05/07/2017	05/07/2017	05/07/2017		Met 70 Day benchmark
57	17/LO/1066	194917	HRA Approvals	GO-LEVEL	05/09/2017	Yes		11/11/2015	10/07/2017	10/08/2017	11/08/2017	11/08/2017	11/08/2017		Met 70 Day benchmark
58	17/EM/0075	222172	HRA Approvals	Evaluating the tolerance, compliance and acceptability of a nutritionally complete, high energy, high protein, enteral feed in adults – a pilot study	06/07/2017	Yes			13/06/2017	27/03/2017	19/06/2017	23/06/2017	23/06/2017		Met 70 Day benchmark
59	16/EM/0436	213166	HRA Approvals	Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)	28/02/2017	Yes		31/08/2016	25/01/2017	07/12/2016	31/01/2017	03/02/2017	03/02/2017		Met 70 Day benchmark
60	17/WS/0008	218692	HRA Approvals	Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab	31/05/2017	Yes			27/04/2017	24/03/2017	04/05/2017	09/05/2017	09/05/2017		Met 70 Day benchmark
61	16/EM/0454	216558	HRA Approvals	A Multicentre, Seroprevalence Study of Subjects With Haemophilia B	20/03/2017	Yes		06/10/2016	06/02/2017	05/12/2016	09/02/2017	28/02/2017	28/02/2017		Met 70 Day benchmark
62	16/WS/0199	214145	HRA Approvals	An Uncontrolled, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy	26/07/2017	Yes			09/06/2017	19/12/2016	20/06/2017	26/06/2017	26/06/2017		Eligible patients seen during the relevant period but did not consent to participate in the trial
63	17/YH/0076	208944	HRA Approvals	Controlling and lowering blood pressure with the MobiusHD defining efficacy markers	06/09/2017	Yes			13/07/2017	18/05/2017	21/07/2017	31/07/2017	31/07/2017		Met 70 Day benchmark
64	17/LO/0369	221479	HRA Approvals	Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples	25/09/2017	Yes			28/07/2017	19/05/2017	08/01/2017	21/08/2017	21/08/2017		Met 70 Day benchmark
65	16/ES/0130	211515	HRA Approvals	A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids	22/05/2017	Yes		24/11/2016	22/03/2017	29/11/2016	29/03/2017	03/05/2017	03/05/2017		Met 70 Day benchmark
66	16/SC/0387	202827	HRA Approvals	Assessment of the effect of Positive Airway Pressure on energy and vitality in mild Obstructive Sleep Apnea patients.	03/02/2017	Yes		20/09/2016	30/11/2016	26/10/2016	06/12/2016	16/12/2016	16/12/2016		Met 70 Day benchmark
67	17/WS/0030	191416	HRA Approvals	A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	27/06/2017	Yes			20/04/2017	12/04/2017	25/04/2017	15/06/2017	15/06/2017		Met 70 Day benchmark
68	16/WM/0507	218607	HRA Approvals	Evaluate the efficacy at 52 weeks of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adalimumab monotherapy in patients with active psoriatic arthritis (AIN457 F2366)	27/06/2017	Yes		05/01/2017	20/04/2017	01/03/2017	13/06/2017	19/06/2017	19/06/2017		Met 70 Day benchmark
69	16/LO/1112	204396	HRA Approvals	A Phase III, randomised, double-blind, multicentre, parallel group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus enofovir/emtricitabine in HIV-1-infected treatment-naïve adults	28/12/2016	Yes		05/09/2016	20/10/2016	05/09/2016	21/10/2016	27/10/2016	27/10/2016		Met 70 Day benchmark
70	17/SC/0122	224090	HRA Approvals	AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS)	26/06/2017	Yes			18/04/2017	18/04/2017	21/04/2017	12/05/2017	12/05/2017		Met 70 Day benchmark

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type (NHS Permission / HRA Approval)	Project Short title	Date of First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Date Site Ready to Start	Non Confirmation Status	Reason for delay in recruiting first participant
71	16/EE/0337	208154	HRA Approvals	A One-Month Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant Compared with Zolpidem in Subjects 55 Years and Older with Insomnia Disorder		No		15/06/2016	09/12/2016	25/10/2016	15/12/2016	04/01/2017	04/01/2017		Other
72	17/EE/0080	220727	HRA Approvals	A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen		No			26/05/2017	09/06/2017	29/06/2017	19/07/2017	19/07/2017		Contracting delays
73	17/LO/0573	222332	HRA Approvals	Proof-of-concept of BI 655130 in patients with ulcerative colitis on TNF inhibitor therapy with incomplete disease control		No			24/04/2017	09/06/2017	12/06/2017	23/06/2017	23/06/2017		Relevant permissions delayed and not granted in time
74	17/SS/0021	213673	HRA Approvals	A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults with Dravet Syndrome (Cohort 2)	19/09/2017	No			04/07/2017	14/06/2017	04/07/2017	11/07/2017	11/07/2017		Rare or very rare diseases studies
75	16/EE/0243	207331	HRA Approvals	A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	06/02/2017	No		03/08/2016	18/11/2016	01/08/2016	23/11/2016	05/12/2016	05/12/2016		No eligible patients seen during the reported period
76	17/WM/0063	220488	HRA Approvals	Ex vivo assessment of the allergenicity and immunogenicity of ASIT+™ products for peanut, cow's milk and egg white allergies	31/07/2017	No			28/04/2017	21/03/2017	16/05/2017	25/05/2017	25/05/2017		Eligible patients seen during the relevant period but did not consent to participate in the trial
77	16/EM/0324	204032	HRA Approvals	A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer's Disease	14/06/2017	No		16/11/2016	13/02/2017	11/01/2017	23/02/2017	03/03/2017	03/03/2017		Eligible patients seen during the relevant period but did not consent to participate in the trial
78	16/WM/0170	195010	HRA Approvals	An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)	10/10/2017	No			09/06/2017	21/06/2016	19/06/2017	12/07/2017	12/07/2017		No eligible patients seen during the reported period
79	16/WS/0109	199365	HRA Approvals	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy	19/04/2017	No		09/03/2016	12/12/2016	10/10/2016	16/12/2016	17/02/2017	17/02/2017		Relevant permissions delayed and not granted in time
80	16/LO/1732	202960	HRA Approvals	Clinical Evaluation of Safety & Effectiveness of the BackBest Medical Moderato System in Patients with Hypertension: A Double A Blind Randomized Trial	06/06/2017	No		23/10/2015	18/01/2017	01/02/2017	29/12/2016	13/02/2017	13/02/2017		Relevant permissions delayed and not granted in time
81	15/LO/2100	192155	HRA Approvals	TO-TAS-102-302 Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Metastatic Gastric Cancer Refractory to Standard Treatments	10/07/2017	No			20/02/2017	24/01/2017	23/02/2017	20/03/2017	20/03/2017		No eligible patients seen during the reported period
82	14/LO/1486	159398	HRA Approvals	CONFIDENTIAL Title: A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)	30/03/2017	No		26/07/2016	01/11/2016	27/09/2016	14/11/2016	22/11/2016	22/11/2016		No eligible patients seen during the reported period
83	16/NE/0142	202233	HRA Approvals	A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer	06/04/2017	No		03/06/2016	04/11/2016	17/11/2016	17/10/2016	17/11/2016	17/11/2016		Eligible patients seen during the relevant period but did not consent to participate in the trial
84	17/EM/0014	219556	HRA Approvals	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority study comparing standard wound closure technique with drains (control) to standard wound closure techniques with TissuGlu and no drains (test) in Mastectomy.	25/09/2017	No			21/04/2017	12/07/2017	05/02/2017	30/05/2017	30/05/2017		Other
85	16/WM/0473	213847	HRA Approvals	A Phase IIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in participants with Advanced Malignancies	09/05/2017	No		09/12/2016	25/10/2016	02/03/2017	30/01/2017	15/03/2017	15/03/2017		Relevant permissions delayed and not granted in time

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type (NHS Permission / HRA Approval)	Project Short title	Date of First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Date Site Ready to Start	Non Confirmation Status	Reason for delay in recruiting first participant
86	16/LO/1509	208393	HRA Approvals	A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate CR (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy	18/05/2017	No		12/09/2016	02/11/2016	03/11/2016	08/11/2016	15/11/2016	15/11/2016		No eligible patients seen during the reported period
87	16/LO/1709	212830	HRA Approvals	NASH NN9931-4296, a phase 2 clinical trial investigating the efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis,		No		18/08/2016	03/03/2017	08/11/2016	07/03/2017	10/03/2017	10/03/2017		Eligible patients seen during the relevant period but did not consent to participate in the trial
88	16/NI/0129	177983	HRA Approvals	A randomised double blind (sponsor unblinded), single and repeat ascending dose First Time in Human study in healthy subjects, cold urticaria and chronic spontaneous urticaria subjects to investigate safety, tolerability, pharmacodynamics and pharmacokinetics of topically applied GSK2646264		No		04/03/2016	27/01/2017	16/11/2016	31/01/2017	03/02/2017	03/02/2017		No eligible patients seen during the reported period
89	16/LO/2126	218039	HRA Approvals	A randomized trial comparing the ELUVIA™ drug-eluting stent versus bare Metal self-expanding nitinol stents in the treatment of superficial femoral and/or proximal popliteal arteries		No			27/06/2017	24/02/2017	29/06/2017	12/07/2017	12/07/2017		Eligible patients seen during the relevant period but did not consent to participate in the trial
90	16/SC/0567	215817	HRA Approvals	An exploratory tumor biopsy-driven study to understand the relationship between biomarkers and indicators of clinical response in immunomodulatory treatment-naïve unresectable stage III/IV melanoma patients receiving REGN2810 (anti-PD-1).		No			09/05/2017	15/12/2016	16/05/2017	24/05/2017	24/05/2017		No eligible patients seen during the reported period
91	16/EM/0465	214926	HRA Approvals	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy		No		13/02/2017	13/02/2017	19/01/2016	22/02/2017	03/03/2017	03/03/2017		No eligible patients seen during the reported period
92	16/WS/0114	200445	HRA Approvals	A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS		No		08/10/2015	09/11/2016	27/09/2016	15/11/2016	01/12/2016	01/12/2016		Eligible patients seen during the relevant period but did not consent to participate in the trial
93	16/LO/1811	214264	HRA Approvals	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS		No		24/10/2016	15/02/2017	05/12/2016	03/03/2017	13/03/2017	13/03/2017		No eligible patients seen during the reported period
94	16/LO/1442	206894	HRA Approvals	A Phase 4, Double-Blind, Randomised, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa		No			05/04/2017	09/01/2017	12/04/2017	05/05/2017	05/05/2017		Eligible patients seen during the relevant period but did not consent to participate in the trial
95	16/EM/0512	215840	HRA Approvals	A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION-POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA		No		18/10/2016	06/03/2017	28/02/2017	20/03/2017	05/04/2017	05/04/2017		No eligible patients seen during the reported period
96	16/LO/0985	202286	HRA Approvals	A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in subjects with Resected Esophageal, or Gastroesophageal Junction Cancer		No			14/02/2017	10/08/2016	28/02/2017	20/03/2017	20/03/2017		No eligible patients seen during the reported period
97	16/NI/0098	206982	HRA Approvals	Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV)		No		08/12/2016	16/02/2017	11/08/2016	14/03/2017	23/03/2017	23/03/2017		No eligible patients seen during the reported period
98	16/LO/1469	210481	HRA Approvals	A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy		No		25/04/2016	07/11/2016	07/10/2016	30/11/2016	13/12/2016	13/12/2016		No eligible patients seen during the reported period
99	16/WM/0513	217953	HRA Approvals	A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement		No			03/04/2017	01/12/2016	25/04/2017	11/05/2017	11/05/2017		Relevant permissions delayed and not granted in time
100	17/LO/0641	221152	HRA Approvals	PROMESA: Promotion of a healthy gut microbiome in elective caesarean section arrivals		No			26/05/2017	01/08/2017	21/08/2017	31/08/2017	31/08/2017		Relevant permissions delayed and not granted in time

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type (NHS Permission / HRA Approval)	Project Short title	Date of First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Date Site Ready to Start	Non Confirmation Status	Reason for delay in recruiting first participant
101	15/LO/1681	185104	HRA Approvals	A Phase III, double-blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD)	23/08/2017	No			26/05/2017	07/06/2016	31/05/2017	14/06/2017	14/06/2017		Staff availability issues at site
102	17/SC/0023	220276	HRA Approvals	A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn's disease	24/05/2017	No		03/01/2017	15/02/2017	08/02/2017	22/02/2017	04/04/2017	04/04/2017		Relevant permissions delayed and not granted in time
103	17/LO/0113	219400	HRA Approvals	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease	18/08/2017	No			03/03/2017	28/04/2017	25/05/2017	15/06/2017	15/06/2017		Relevant permissions delayed and not granted in time
104	16/WM/0448	212745	HRA Approvals	A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir		No			13/04/2017	08/02/2017	22/04/2017	04/05/2017	04/05/2017		Other
105	17/EE/0081	219405	HRA Approvals	An open label, single arm pilot study of OncoSil™, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies		No			25/05/2017	08/05/2017	09/06/2017	06/07/2017	06/07/2017		Relevant permissions delayed and not granted in time
106	17/NW/0180	220257	HRA Approvals	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy		No		11/10/2016	11/05/2017	04/04/2017	25/05/2017	23/06/2017	23/06/2017		Relevant permissions delayed and not granted in time
107	16/LO/0877	202257	HRA Approvals	A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB*(MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY		No		02/08/2016	17/10/2016	05/09/2016	04/11/2016	22/12/2016	22/12/2016		Relevant permissions delayed and not granted in time
108	17/SC/0033	218114	HRA Approvals	A phase 3 randomized, open-label, multicenter study comparing isatuximab (SAR650984) in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma	01/08/2017	No			04/05/2017	29/03/2017	15/05/2017	23/05/2017	23/05/2017		Delays caused by sponsor
109	17/LO/0017	213632	HRA Approvals	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	14/08/2017	No		05/08/2016	17/05/2017	08/03/2017	01/06/2017	27/06/2017	27/06/2017		Relevant permissions delayed and not granted in time
110	13/LO/0867	126972	HRA Approvals	Double-blind, Randomised, Multicentre, Study of Nintedanib in Combination with Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy versus Placebo in Combination with Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients with Unresectable Malignant Pleural Mesothelioma	12/07/2017	No		22/06/2016	20/01/2017	08/07/2016	23/01/2017	03/02/2017	03/02/2017		Delays caused by sponsor
111	16/WM/0285	202235	HRA Approvals	A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mixed Dyslipidemia		No			14/06/2017	28/04/2017	20/06/2017	30/06/2017	30/06/2017		Delays caused by sponsor
112	17/WS/0072	221444	HRA Approvals	Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation – in atrial fibrillation (ENVISAGE TAVI-AF)		No			03/07/2017	06/06/2017	17/07/2017	27/07/2017	27/07/2017		Delays caused by sponsor
113	16/LO/0708	200170	HRA Approvals	A Phase I Study Evaluating TAS-116 in Patients With Advanced Solid Tumors		No			15/06/2017	30/06/2017	19/07/2017	26/07/2017	26/07/2017		Relevant permissions delayed and not granted in time
114	16/NI/0116	203047	HRA Approvals	Molecular Biomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection study in Crohn's disease patients (MOBIDIC)		No		01/09/2016	01/12/2016	05/10/2016	22/12/2016	12/01/2017	12/01/2017		Delays caused by sponsor

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type (NHS Permission / HRA Approval)	Project Short title	Date of First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Date Site Ready to Start	Non Confirmation Status	Reason for delay in recruiting first participant
115	16/YH/0489	197733	HRA Approvals	A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early intervention compared to standard treatment with narrow band UVB		No			30/06/2017	02/02/2017	03/08/2017	14/08/2017	14/08/2017		Delays caused by sponsor
116	16/SC/0651	213404	HRA Approvals	An evaluation of the tolerance, compliance and acceptability of a ready to use, liquid, high energy, high protein, peptide-based feed for adults in need of nutrition support – a pilot study		No			12/04/2017	13/01/2017	20/04/2017	02/06/2017	02/06/2017		Study suspended by sponsor
117	15/LO/1950	184545	HRA Approvals	A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence 1)		No			06/04/2017	18/01/2017	18/04/2017	02/06/2017	02/06/2017		Relevant permissions delayed and not granted in time
118	16/LO/0779	203698	HRA Approvals	An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQGE031C2201.		No		27/05/2016	09/11/2016	13/07/2016	18/01/2017	01/02/2017	01/02/2017		Contracting delays
119	16/LO/1624	213198	HRA Approvals	An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome		No		17/11/2016	10/11/2016	18/11/2016	21/11/2016	14/03/2017	14/03/2017		Delays caused by sponsor
120	16/LO/2195	219516	HRA Approvals	CO-338-052: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency		No			29/03/2017	28/03/2017	16/05/2017	17/08/2017	17/08/2017		Relevant permissions delayed and not granted in time
121	17/EE/0128	222308	HRA Approvals	A Multi-Center, Open-Label Trial Investigating the Efficacy and Safety of Continued Treatment with Tisotumab Vedotin in Patients with Solid Tumors Known to Express Tissue Factor		No			31/03/2017	19/05/2017	24/08/2017	14/09/2017	14/09/2017		Contracting delays
122	16/LO/0423	198451	HRA Approvals	A Phase 1 Trial: A Phase 1 trial of SRA737 (a Chk1 inhibitor) administered orally in subjects with advanced cancer		Within 70 days			15/09/2017	19/05/2016	18/09/2017	19/09/2017	19/09/2017		Within 70 days
123	17/LO/0418	220385	HRA Approvals	A Phase II Multi Centre Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung		Within 70 days		24/10/2016	06/09/2017	12/06/2017	07/09/2017	11/09/2017	11/09/2017		Within 70 days
124	17/NW/0175	222859	HRA Approvals	A Phase 1b, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia		Within 70 days			04/08/2017	19/05/2017	04/08/2017	09/08/2017	09/08/2017		Within 70 days
125	17/LO/1147	222154	HRA Approvals	A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.		Within 70 days			26/09/2017	10/08/2017	29/09/2017	04/10/2017	04/10/2017		Within 70 days
126	17/SC/0236	226436	HRA Approvals	Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults ('PALISADE') Follow-On Study"		Within 70 days			01/09/2017	08/06/2017	04/09/2017	09/09/2017	09/09/2017		Within 70 days
127	17/LO/0997	226705	HRA Approvals	A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without Inhibitors		Within 70 days			23/08/2017	17/07/2017	24/08/2017	31/08/2017	31/08/2017		Within 70 days
128	17/NW/0374	226708	HRA Approvals	A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors.		Within 70 days			22/08/2017	18/07/2017	24/08/2017	31/08/2017	31/08/2017		Within 70 days
129	17/LO/0425	222355	HRA Approvals	AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK RECEIVING REGN2810 (ANTI-PD-1)		Within 70 days			30/08/2017	11/04/2017	07/09/2017	12/09/2017	12/09/2017		Within 70 days
130	17/LO/0284	221453	HRA Approvals	A study of single doses to evaluate the safety, tolerability, pharmacokinetics and target engagement nebulised GSK3008348 in idiopathic pulmonary fibrosis patients, using positron emission tomography (PET)		Within 70 days		17/02/2017	12/09/2017	28/03/2017	19/09/2017	26/09/2017	26/09/2017		Within 70 days
131	17/NW/0292	223951	HRA Approvals	Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies		Within 70 days			12/09/2017	27/07/2017	14/09/2017	26/09/2017	26/09/2017		Within 70 days

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type (NHS Permission / HRA Approval)	Project Short title	Date of First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Date Site Ready to Start	Non Confirmation Status	Reason for delay in recruiting first participant
132	17/LO/0145	214065	HRA Approvals	A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and lymphomas		Within 70 days			11/09/2017	08/08/2017	19/09/2017	26/09/2017	26/09/2017		Within 70 days
133	17/LO/0525	221541	HRA Approvals	A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORTÂ® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3).		Within 70 days			22/08/2017	30/06/2017	25/08/2017	06/09/2017	06/09/2017		Within 70 days
134	15/SC/0404	183198	HRA Approvals	The effect of oc000459 on eosinophilic airway inflammation and asthma control in subjects with refractory eosinophilic asthma: a randomised, double blind, placebo controlled trial		Within 70 days			18/09/2017	15/08/2016	25/09/2017	06/10/2017	06/10/2017		Within 70 days
135	17/LO/0409	217785	HRA Approvals	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)		Within 70 days			30/08/2017	30/03/2017	07/09/2017	18/09/2017	18/09/2017		Within 70 days
136	16/LO/0324	190140	HRA Approvals	REDUCER-I: An Observational Study of the Neovasc Reducer™ System		Within 70 days			24/08/2017	22/08/2016	24/08/2017	12/09/2017	12/09/2017		Within 70 days
137	17/SC/0253	226685	HRA Approvals	Abemaciclib in Node Positive Early Stage Hormone Receptor-Positive (HR+), HER2		Within 70 days			18/08/2017	05/07/2017	23/08/2017	06/09/2017	06/09/2017		Within 70 days
138	17/EM/0183	220783	HRA Approvals	A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal polyps		Within 70 days			11/08/2017	28/06/2017	21/08/2017	31/08/2017	31/08/2017		Within 70 days
139	17/YH/0098	220504	HRA Approvals	Evaluation of Ablation Index and VISITAG™ use for Pulmonary Vein Isolation (PVI) in Patients with Paroxysmal Atrial Fibrillation (PAF)		Within 70 days			13/09/2017	24/07/2017	21/09/2017	04/10/2017	04/10/2017		Within 70 days
140	17/LO/0100	200545	HRA Approvals	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens		Within 70 days			24/07/2017	25/04/2017	04/08/2017	15/08/2017	15/08/2017		Within 70 days
141	17/LO/0041	219676	HRA Approvals	CardioMEMS HF System OUS Post Approval Study		Within 70 days			31/07/2017	06/03/2017	10/08/2017	29/08/2017	29/08/2017		Within 70 days
142	17/LO/1101	227790	HRA Approvals	Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF) (CONVERGE)		Within 70 days			06/09/2017	30/08/2017	11/09/2017	09/10/2017	09/10/2017		Within 70 days